Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.eris.co.in | |
Market Cap | 11,839.53 Cr. | |
Enterprise Value(EV) | 12,450.02 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 28.40 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 30.64 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.01 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 184.72 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.71 | Calculated using Price: 870.25 |
Dividend Yield | 0.84 | Period Ending 2023-03 |
No. of Shares Subscribed | 13.60 Cr. | 136,047,466 Shares |
FaceValue | 1 | |
About Eris Lifesciences Ltd. | ||
The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders. |
1 Day |
|
-0.16% |
1 Week |
|
+2.55% |
1 Month |
|
+2.77% |
3 Month |
|
-4.29% |
6 Month |
|
-0.12% |
1 Year |
|
+45.12% |
2 Year |
|
+23.40% |
5 Year |
|
+35.94% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 40.3 | 47.68 | 56.9 | 41.3 | 28.96 | 24.28 | 24.78 | 23.33 | 18.25 | |
Return on Capital Employed (%) | 49.25 | 54.56 | 62.56 | 35.76 | 26.54 | 25.44 | 27.6 | 25.29 | 17.31 | |
Return on Assets (%) | 28.59 | 36.17 | 43.89 | 27.31 | 20.02 | 20.33 | 22.62 | 21.27 | 13.4 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 266 | 300 | 567 | 861 | 1,151 | 1,296 | 1,576 | 1,908 | 2,196 | 2,412 | |
Non Curr. Liab. | 19 | 20 | 12 | 248 | -66 | -80 | -109 | -79 | 729 | 655 | |
Curr. Liab. | 65 | 69 | 129 | 294 | 377 | 220 | 235 | 283 | 521 | 497 | |
Minority Int. | 4 | 3 | 24 | 25 | 18 | 0 | 25 | 16 | |||
Equity & Liab. | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 3,471 | 3,580 | |
Non Curr. Assets | 191 | 169 | 463 | 1,061 | 827 | 902 | 1,167 | 1,402 | 2,629 | 2,619 | |
Curr. Assets | 163 | 222 | 270 | 367 | 653 | 535 | 536 | 711 | 843 | 961 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 3,471 | 3,580 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 1,861 | |
Other Income | 3 | 3 | 25 | 26 | 32 | 16 | 9 | 26 | 11 | 10 | |
Total Income | 549 | 600 | 775 | 882 | 1,014 | 1,090 | 1,221 | 1,373 | 1,696 | 1,871 | |
Total Expenditure | -424 | -425 | -480 | -533 | -637 | -706 | -781 | -862 | -1,148 | -1,216 | |
PBIDT | 125 | 175 | 294 | 349 | 377 | 384 | 439 | 511 | 548 | 655 | |
Interest | 0 | 0 | -1 | -11 | -23 | -2 | -2 | -4 | -26 | -61 | |
Depreciation | -16 | -20 | -23 | -26 | -36 | -50 | -43 | -65 | -117 | -164 | |
Taxation | -20 | -20 | -24 | -17 | -26 | -35 | -39 | -36 | -30 | -52 | |
Exceptional Items | |||||||||||
PAT | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 379 | |
Minority Interest | 0 | -1 | 0 | -1 | 0 | 0 | 0 | 8 | 8 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 89 | 134 | 247 | 294 | 291 | 297 | 355 | 406 | 382 | 386 | |
Adjusted EPS | 6 | 10 | 18 | 21 | 21 | 22 | 26 | 30 | 28 | 28 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 90 | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | |
Cash Fr. Inv. | -83 | -92 | -44 | -184 | -590 | -5 | 123 | -323 | -320 | -982 | |
Cash Fr. Finan. | -2 | 0 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | |
Net Change | 5 | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | -2 | |
Cash & Cash Eqvt | 7 | 5 | 9 | 2 | 11 | 8 | 67 | 37 | 51 | 56 |
Tue, 16 Apr 2024
Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulation 2015 For The Period Ended March 31 2024. Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulation 2015 for the period ended March 31 2024. |
Tue, 09 Apr 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Allotment of Equity shares. |
Sat, 06 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 |
Thu, 18 Apr 2024 |
Higher Delivery Quantity |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |
Opening at Low |
Close Within 52 Week High Zone |